DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Post Marketing Surveillance Study of Cuprimine

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Scleroderma

Intervention: Cuprimine (penicillamine) (Drug)

Phase: N/A

Status: No longer available

Sponsored by: Merck Sharp & Dohme Corp.

Summary

Cuprimine (penicillamine) was made available in the Philippines by the Sponsor under a Compassionate Special Permit issued by the Bureau of Food and Drugs. Physicians were able to request the drug for their patients from the Sponsor. A Clinical Study Report form was completed for each purchase of Cuprimine.

Clinical Details

Official title: Post Marketing Surveillance Study of Cuprimine (MK-0172-001)

Study design: N/A

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- None

Exclusion Criteria:

- None

Locations and Contacts

Additional Information


Last updated: November 12, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017